 Biocept Inc NASDAQ:BIOC posted first-quarter results that saw its revenue jump 12 year-over-year on the back of its RT-PCR coronavirus COVID-19 testing services. For the period ended March 31, 2022, the San Diego, California-based provider of molecular diagnostic assays, products, and services, reported revenue of 19.9 million, compared to 17.8 million in 1Q 2021. 